Sector
PharmaceuticalsOpen
₹1.9Prev. Close
₹2Turnover(Lac.)
₹0.99Day's High
₹2.1Day's Low
₹1.952 Week's High
₹052 Week's Low
₹0Book Value
₹-1.53Face Value
₹5Mkt Cap (₹ Cr.)
7.16P/E
0EPS
0Divi. Yield
0
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 17.05 | 17.05 | 17.05 | 17.05 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -22.28 | -22.13 | -19.1 | 4.57 |
Net Worth | -5.23 | -5.08 | -2.05 | 21.62 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 106.66 | 139.55 | 109.14 | 91.04 |
yoy growth (%) | -23.56 | 27.86 | 19.87 | 17.33 |
Raw materials | -116.55 | -108.63 | -81.75 | -72.26 |
As % of sales | 109.26 | 77.84 | 74.9 | 79.37 |
Employee costs | -7.33 | -4.06 | -3.67 | -3.45 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -47.82 | 5.64 | 0.87 | -8.83 |
Depreciation | -4.7 | -4.03 | -3.87 | -2.21 |
Tax paid | 0 | -1.17 | -0.73 | 1.7 |
Working capital | -37.04 | -0.89 | 1.39 | -20.04 |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -23.56 | 27.86 | 19.87 | 17.33 |
Op profit growth | -383.21 | 35.97 | -635.59 | -114.31 |
EBIT growth | -423.16 | 125.44 | -244.96 | -135.63 |
Net profit growth | -2,284.46 | 1,472.98 | -102.22 | -178.94 |
| Particulars (Rupees in Crores.) | Mar-2015 | Mar-2014 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Gross Sales | 72.23 | 68.41 | 44.7 | 36.22 |
Excise Duty | 7.19 | 6.73 | 0 | 0 |
Net Sales | 65.04 | 61.68 | 44.7 | 36.22 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 0.2 | 0.1 | 0.17 | 0.07 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Mukesh D Naik
Independent Director
Vinod Laxman Parab
Non-Exec. & Independent Dir.
Nitin Desai
Company Secretary
Nancy Napoleon
Non-Exec. & Independent Dir.
Leena Chitalia
Plot No N-92,
MIDC-Tarapur Boisar,
Maharashtra - 401506
Tel: -
Website: http://www.nutraplusindia.com
Email: nutraplus@gmail.com
Unit No 1 Luthra Ind,
Andheri Kurla Road, Safed Pool Andheri(E,
Mumbai - 400 072
Tel: 91-22-2851 5606
Website: www.sharexindia.com
Email: sharexndia@vsnl.com
Summary
Nutraplus Products (India) Limited was originally incorporated as a private limited company on 6 Feb.90. It was subsequently converted into a public limited company with effect from 13 Jun.92. The com...
Read More
Reports by Nutraplus India Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
